GW 468816

Drug Profile

GW 468816

Alternative Names: 468816; GW-468816

Latest Information Update: 24 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator GlaxoSmithKline
  • Developer GlaxoSmithKline; National Institute on Drug Abuse
  • Class Antimigraines; Smoking cessation therapies
  • Mechanism of Action Glycine antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Smoking withdrawal
  • Discontinued Migraine

Most Recent Events

  • 10 Dec 2009 Efficacy data from three clinical trials presented at the 48th Annual Meeting of the American College of Neuropsychopharmacology (ACNP-2009)
  • 11 Jan 2008 Phase II development is ongoing
  • 30 Apr 2002 Discontinued - Phase-I for Migraine in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top